A Briefing Desk, Not a Clinic

What this desk is

pitaspeptides is an independent digest of the published literature on metabolic and weight-research peptides, organised around a single question: where does a compound enter the body's satiety signalling, and does that placement predict what happens in a trial?

That framing is a deliberate choice. Most writing in this category is organised by product or by result — which compound produces the largest percentage. Organising by mechanism instead makes the differences legible: it explains why two structurally similar molecules behave similarly, why a third that skips the appetite circuit behaved differently in humans, and why the class's most common side effect is inseparable from its intended effect.

Nothing here is for sale. This site does not dispense, source, supply or recommend any compound, does not carry sponsored placement, and has no clinical relationship with any reader. It has one job: to represent the published record accurately, including the parts of that record that are inconvenient or absent.

How a briefing is built

Every compound page follows the same structure, in the same order: what it is, how it works, what the research shows, what is reported and what to watch, and where it sits in the wider satiety picture. Consistency is the point — a reader comparing three compounds should not have to work out three different layouts.

Evidence is graded openly and labelled at the point of use. A randomised controlled trial is named as such, with its participant count, duration and effect size. An animal study is identified as an animal study every time it is cited, never quietly promoted into human evidence. A structural or in-vitro finding is described as mechanism, not outcome. Regulatory status is stated plainly on each page, because approved, investigational and unapproved are three genuinely different things.

Community reports appear in their own labelled section on every compound page. They are anecdotal, not clinical evidence; they carry no doses; and they are included because what people notice is legitimate information about a compound even when it is not evidence of efficacy. Where community reports contradict the trial data, both are stated. Where they agree, that agreement is noted rather than treated as proof.

Every quantitative claim carries a bracketed number keyed to the reference list, which gives authors, journal, year and a resolvable link for each source.

Where the briefing stops

This desk does not provide medical advice, does not recommend that any person take any compound, and publishes no dosing, reconstitution or administration guidance. Amounts used in cited trials are reported as facts about those trials — that is a description of what researchers did, not a suggestion for anyone else.

It also does not attempt to be current on regulatory questions that move faster than a literature digest can. Approval status, compounding eligibility and anti-doping classification all change, and each of those should be verified independently at the time of reading rather than taken from this site.

The honest boundary of the whole project is this: a literature digest can say what has been measured, in whom, for how long, and with what result. It cannot say what will happen to any individual, and the questions readers most want answered — durability after stopping, long-term safety of newer agents, how much of the weight lost is muscle — are precisely the ones the published record has not yet closed.